Overview

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Status:
Recruiting
Trial end date:
2022-01-11
Target enrollment:
Participant gender:
Summary
This study is designed investigate the effect of severe hepatic impairment on the pharmacokinetics (PK) of cenobamate.
Phase:
Phase 1
Details
Lead Sponsor:
SK Life Science, Inc.
Treatments:
Cenobamate